Nivolumab: tested in a combination
680 studies: another drug in the study is under test too. Page 4 of 7. Open to participants first (135), then studies with results posted, then the rest; newest registration first within each.
- Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT02819804Phase 1Results postedReport a problem
- Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaActive, not recruitingNCT02758717Phase 2Results postedReport a problem
- Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT02754726Phase 2Results postedReport a problem
- Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02741570Phase 3Results postedReport a problem
- Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor TherapyCompletedNCT02731729Phase 2Results postedReport a problem
- A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCompletedNCT02714218Phase 3Results postedReport a problem
- Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results postedReport a problem
- Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaCompletedNCT02659540Phase 1Results postedReport a problem
- Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung CancerCompletedNCT02659059Phase 2Results postedReport a problem
- Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV MelanomaActive, not recruitingNCT02656706Phase 2Results postedReport a problem
- An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaActive, not recruitingNCT02648997Phase 2Results postedReport a problem
- A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.CompletedNCT02612779Phase 2Results postedReport a problem
- Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7CompletedNCT02601014Phase 2Results postedReport a problem
- Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCompletedNCT02599402Phase 3Results postedReport a problem
- An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCompletedNCT02581631Phase 1/2Results postedReport a problem
- A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02574078Phase 1/2Results postedReport a problem
- A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results postedReport a problem
- Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based ChemotherapyCompletedNCT02538666Phase 3Results postedReport a problem
- Neoadjuvant and Adjuvant Checkpoint BlockadeCompletedNCT02519322Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by SurgeryCompletedNCT02500797Phase 2Results postedReport a problem
- An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated TumorsCompletedNCT02488759Phase 1/2Results postedReport a problem
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02477826Phase 3Results postedReport a problem
- Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic DiseaseTerminatedNCT02469701Phase 2Results postedReport a problem
- Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT02464657Phase 1/2Results postedReport a problem
- Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine LeiomyosarcomaCompletedNCT02428192Phase 2Results postedReport a problem
- Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter TransformationCompletedNCT02420912Phase 2Results postedReport a problem
- Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedNCT02408861Phase 1Results postedReport a problem
- Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT02397720Phase 2Results postedReport a problem
- Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCsCompletedNCT02350764Phase 2Results postedReport a problem
- A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic MalignanciesCompletedNCT02329847Phase 1/2Results postedReport a problem
- An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by ItselfCompletedNCT02320058Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal CancerActive, not recruitingNCT02314169Phase 2Results postedReport a problem
- Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results postedReport a problem
- GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without NivolumabCompletedNCT02243371Phase 2Results postedReport a problem
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingNCT02224781Phase 3Results postedReport a problem
- PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond ProgressionCompletedNCT02213289Phase 2Results postedReport a problem
- Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited DiseaseCompletedNCT02046733Phase 2Results postedReport a problem
- A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid LeukemiaCompletedNCT02011945Phase 1Results postedReport a problem
- Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaActive, not recruitingNCT01703949Phase 2Results postedReport a problem
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results postedReport a problem
- Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)CompletedNCT01642004Phase 3Results postedReport a problem
- Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant MelanomaCompletedNCT01024231Phase 1Results postedReport a problem
- Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction AdenocarcinomaCompletedNCT07529613Phase 1/2Report a problem
- Neoadjuvant Low-dose Immunotherapy in Locally Advanced MMR-deficient Colorectal CancerActive, not recruitingNCT07523763Phase 2Report a problem
- Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.WithdrawnNCT07369791Phase 2Report a problem
- Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT07216833Phase 1Report a problem
- Nivolumab Plus Metformin in Metastatic Renal Cell CarcinomaTerminatedNCT06884683Phase 2Report a problem
- A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERSActive, not recruitingNCT06715241Phase 2Report a problem
- A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With TrastuzumabActive, not recruitingNCT06681298Phase 2Report a problem
- Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung CancerActive, not recruitingNCT06632327Phase 3Report a problem
- Perioperative Immunotherapy for NSCLC (ECTOP-1030)WithdrawnNCT06572722Phase 2Report a problem
- Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic MelanomaActive, not recruitingNCT06566391Phase 2Report a problem
- Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS MalignanciesWithdrawnNCT06466798Phase 1Report a problem
- Nivolumab Plus Gemcitabine in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma-HN17-11CompletedNCT06440187Phase 2Report a problem
- A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerWithdrawnNCT06410534Phase 2Report a problem
- Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable MelanomaWithdrawnNCT06365619Phase 2Report a problem
- ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT06357858Phase 1Report a problem
- Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1CompletedNCT06354387Phase 1Report a problem
- Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedNCT06325683Phase 2Report a problem
- A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)Active, not recruitingNCT06284564Phase 2Report a problem
- Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter's Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaWithdrawnNCT06247540Phase 2Report a problem
- A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainActive, not recruitingNCT06132945Phase 1Report a problem
- A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent GlioblastomaActive, not recruitingNCT06097975Phase 1Report a problem
- Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT06053658Phase 2Report a problem
- LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue SarcomaStatus unknownNCT05876715Phase 1/2Report a problem
- Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal MetastasisActive, not recruitingNCT05802056Phase 1Report a problem
- Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain MetastasesCompletedNCT05704933Early Phase 1Report a problem
- Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)Active, not recruitingNCT05696548Phase 2Report a problem
- DUMAS: Neo-Adjuvant Immunotherapy for Pancoast TumorsActive, not recruitingNCT05684276Phase 2Report a problem
- Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's TransformationActive, not recruitingNCT05672173Phase 2Report a problem
- Intrathecal Double Checkpoint InhibitionActive, not recruitingNCT05598853Phase 1Report a problem
- Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerCompletedNCT05535569Phase 1/2Report a problem
- Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract CarcinomaStatus unknownNCT05509478Phase 2Report a problem
- Chemo-radio-immunotherapy With Nivolumab and Ipilimumab Treatment in Locally Advanced Cervical Cancer PatientsWithdrawnNCT05504642Phase 2Report a problem
- METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by OxaliplatinActive, not recruitingNCT05504252Phase 2Report a problem
- Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2Report a problem
- Study of Relatlimab in Combination With Nivolumab in Chinese ParticipantsCompletedNCT05498480Phase 1Report a problem
- Nivolumab and All-trans Retinoic Acid for Pancreatic CancerStatus unknownNCT05482451Early Phase 1Report a problem
- Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal JunctionActive, not recruitingNCT05480384Phase 2Report a problem
- Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without NivolumabWithdrawnNCT05472623Phase 2Report a problem
- PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical SurgeryActive, not recruitingNCT05468138Phase 2Report a problem
- RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSLStatus unknownNCT05425654Phase 2Report a problem
- A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous MelanomaActive, not recruitingNCT05418972Phase 2Report a problem
- Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def TumorsActive, not recruitingNCT05407441Phase 1/2Report a problem
- Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2Report a problem
- Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaActive, not recruitingNCT05347212Phase 2Report a problem
- Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid TumorsCompletedNCT05302921Phase 2Report a problem
- CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With MelanomaActive, not recruitingNCT05289193Phase 2Report a problem
- Study of NIVOLUMAB/IPILIMUMAB Maintenance in Unresectable Locally Advanced or Metastatic Urothelial CancerCompletedNCT05219435Phase 2Report a problem
- CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer ImmunotherapyActive, not recruitingNCT05215470Phase 2Report a problem
- Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UCActive, not recruitingNCT05200988Phase 2Report a problem
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + BevacizumabTerminatedNCT05199285Phase 2Report a problem
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1Report a problem
- Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA MeasurementsStatus unknownNCT05175235Phase 1/2Report a problem
- Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)CompletedNCT05169957Phase 1Report a problem
- CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or RelapsedActive, not recruitingNCT05162976Phase 1Report a problem
- EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPCActive, not recruitingNCT05150236Phase 2Report a problem
- A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)Active, not recruitingNCT05144854Phase 3Report a problem
- A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese ParticipantsCompletedNCT05136677Phase 2Report a problem